{"id":61067,"date":"2022-02-05T05:45:16","date_gmt":"2022-02-05T05:45:16","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=86492"},"modified":"2022-02-05T05:45:16","modified_gmt":"2022-02-05T05:45:16","slug":"nyxoah-to-present-at-btig-medtech-digital-health-life-science-diagnostic-tools-conference","status":"publish","type":"post","link":"https:\/\/kuwaitnewsgazette.com\/nyxoah-to-present-at-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/","title":{"rendered":"Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference"},"content":{"rendered":"
\n

Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference<\/strong><\/p>\n

Mont-Saint-Guibert, Belgium \u2013 February 4, 2022, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/b>(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually from February 15-17, 2022.<\/p>\n

Olivier Taelman, Nyxoah\u2019s Chief Executive Officer, is scheduled to present a corporate update on Thursday, February 17, 2022, at 8:00am EST. This presentation will not be webcast due to the format of the conference. The Company will also be available for virtual 1×1 meetings with institutional investors registered for the event.<\/p>\n

Nyxoah\u2019s updated Investor Presentation can be accessed on the\u00a0Shareholder Information<\/u><\/a>\u00a0section of the Company\u2019s Investor Relations page.<\/p>\n

About Nyxoah<\/b>
\nNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).\u00a0Nyxoah\u2019s lead solution is the Genio\u00ae system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n

Following the successful completion of the BLAST OSA study, the Genio\u00ae system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.<\/p>\n

For more information, please visit\u00a0http:\/\/www.nyxoah.com\/<\/u><\/a>.<\/p>\n

Caution\u00a0<\/b>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n

Contacts:<\/b>
\nNyxoah<\/b>
\nLoic Moreau, Chief Financial Officer
\ncorporate@nyxoah.com<\/a>
\n+32 473 33 19 80<\/p>\n

Jeremy Feffer, VP IR and Corporate Communications
\njeremy.feffer@nyxoah.com<\/u><\/a>
\n+1 917 749 1494<\/p>\n

Gilmartin Group\u00a0<\/b>
\nVivian Cervantes
\nIR@nyxoah.com<\/u><\/a><\/p>\n

Attachment<\/strong><\/p>\n